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For therapeutic cancer vaccination, the adoptive transfer of mRNA-electroporated dendritic cells (DCs) is frequently performed,
usually with monocyte-derived, cytokine-matured DCs (moDCs). However, DCs are rich in danger-sensing receptors which could
recognize the exogenously delivered mRNA and induce DC activation, hence influencing the DCs’ immunogenicity. Therefore,
we examined whether electroporation of mRNA with a proper cap and a poly-A tail of at least 64 adenosines had any influence
on cocktail-matured moDCs. We used 16 different RNAs, encoding tumor antigens (MelanA, NRAS, BRAF, GNAQ, GNA11, and
WT1), and variants thereof. None of those RNAs induced changes in the expression of CD25, CD40, CD83, CD86, and CD70
or the secretion of the cytokines IL-8, IL-6, and TNF𝛼 of more than 1.5-fold compared to the control condition, while an mRNA
encoding anNF-𝜅B-activation protein as positive control inducedmassive secretion of the cytokines. To determine whethermRNA
electroporation had any effect on the whole transcriptome of the DCs, we performed microarray analyses of DCs of 6 different
donors. None of 60,000 probes was significantly different betweenmock-electroporated DCs andMelanA-transfected DCs. Hence,
we conclude that no transcriptional programs were induced within cocktail-matured DCs by electroporation of single tumor-
antigen-encoding mRNAs.
1. Introduction
During the last decade, immunotherapy has evolved as a
new pillar of cancer treatment [1]. Therapeutic vaccination
with dendritic cells (DCs) is a safe and well-established
strategy [2–4]. A deeper understanding of DC maturation
and activation together with efficient, GMP-compliant and
reproducible antigen- (Ag-) loading strategies is the key to
success. One technology that has proven suitable in this
context is mRNA transfection [3, 5, 6], which can be utilized,
on the one hand, to load mature DCs with tumor antigen
[7–9], and on the other hand, to deliver maturation and
activation signals to the DCs. The latter is usually achieved
by using mRNA that encodes DC-activating proteins, like
constitutively active inhibitor of kappa B kinase (IKK) [10] or
CD40L, alone [11], or combined with a constitutively active
TLR [12].
However, since DCs comprise a whole battery of nucleic
acid receptors on their surface, in their endosomes, and in
their cytoplasm [13, 14], the transfected mRNA itself, inde-
pendently from the encoded protein, may deliver a matura-
tion signal. Single-stranded (ss)RNAwas reported to activate
TLR7 and TLR8 on DCs [15–17] and TLR3 can be activated
by short double-strand stretches in exogenous mRNA [18,
19]. RIG-I-like receptors (RLR) recognize various viral RNA
species in the cytoplasm [20] and may be capable of sensing
transfected RNA as well. Bacterial RNA is a potent DC mat-
uration stimulus, but the specific receptors are yet unknown
[21].
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Table 1: mRNAs used for transfection.
Antigen Description Abbreviation
MelanA MelanA (MART1) full length wild type MelanA
NRAS NRAS-fragment 40 AA around mutation site 61 with DC-LAMP signal and flag-tag NRAS-DCL
NRAS Q61K NRAS-fragment 40 AA around mutation Q61K with DC-LAMP signal and flag-tag NRAS-DCL K
NRAS Q61R NRAS-fragment 40 AA around mutation Q61R with DC-LAMP signal and flag-tag NRAS-DCL R
BRAF BRAF-fragment 67 AA around mutation site 600 with flag-tag BRAF
BRAF V600E BRAF-fragment 67 AA around mutation V600E with flag-tag BRAF E
BRAF BRAF-fragment 67 AA around mutation site 600 with DC-LAMP signal and flag-tag BRAF-DCL
BRAF V600E BRAF-fragment 67 AA around mutation V600E with DC-LAMP signal and flag-tag BRAF-DCL E
GNAQ GNAQ-fragment 47 AA around mutation site 209 with DC-LAMP signal and flag-tag GQ-DCL
GNAQ Q209P GNAQ-fragment 47 AA around mutation Q209P with DC-LAMP signal and flag-tag GQ-DCL P
GNAQ Q209L GNAQ-fragment 47 AA around mutation Q209L with DC-LAMP signal and flag-tag GQ-DCL L
GNA11 GNA11-fragment 47 AA around mutation site 209 with DC-LAMP signal and flag-tag G11-DCL
GNA11 Q209P GNA11-fragment 47 AA around mutation Q209P with DC-LAMP signal and flag-tag G11-DCL P
GNA11 Q209L GNA11-fragment 47 AA around mutation Q209L with DC-LAMP signal and flag-tag G11-DCL L
WT-1 Wilms tumor 1 full length wild type WT1
GNAQ Wilms tumor 1 full length with DC-LAMP signal and flag-tag WT1-DCL
𝐼𝐾𝐾𝛽
1 Constitutively active stabilized IKK𝛽 to activate NF-𝜅B IKK𝛽
1Not a tumor antigen, but a DC-activating protein.
In the design of clinical vaccination protocols, it is, how-
ever, pivotal to know which maturation program is induced
in the DCs and whether and how any additional maturation
stimulus might distort the intended mature phenotype of
the vaccine DCs. When DCs (usually monocyte-derived
ones) are generated, matured, and Ag-loaded for clinical
application, one requires a well-defined product, and any
remaining insecurity about any factors that influence the
phenotype of the DCs should be resolved.
Hence, we took the effort to carefully comparemonocyte-
derived cytokine-matured DCs that were electroporated
without RNAwith DCs that were electroporated with various
in vitro-transcribed mRNAs. We analyzed the DCs’ phe-
notype and cytokine secretion and, for mRNA, encoding
the tumor antigen MelanA, a transcriptome analysis was
performed, to detect if any of these features would be changed
by the introduced mRNA.
2. Materials and Methods
2.1. Cells and Reagents. Monocyte-derived dendritic cells
(DCs) were generated from blood, obtained from healthy
donors following informed consent and approval by the
institutional review board as described before [9]. PBMCs
were purified by density centrifugation, and monocytes were
separated from the nonadherent fraction (NAF) by plastic
adherence and differentiated to DCs over 6 days in DC
medium (RPMI 1640 (Lonza, Verviers, Belgium) containing
1% heat-inactivated autologous plasma, 2mM L-glutamine
(Lonza), and 20mg/L gentamicin (PAA, Pasching, Austria))
with GM-CSF (800 IU/mL; CellGenix, Freiburg, Germany,
PeproTech, Hamburg, Germany, and Miltenyi Biotec, Ber-
gisch Gladbach, Germany) and IL-4 (250 IU/mL; CellGenix,
PeproTech, and Miltenyi Biotec) in the absence of fetal calf
serum, as described before [9].DCswerematured (mDCs) on
day 6 for 24 h with 200 IU/mL IL-1𝛽 (CellGenix), 1000U/mL
IL-6 (CellGenix), 10 ng/mL TNF𝛼 (Beromun, Boehringer
Ingelheim Pharma, Germany), and 1 𝜇g/mL PGE
2
(Pfizer,
Zurich, Switzerland). mDCs were used for electroporation
with mRNA after maturation.
2.2. In Vitro RNA Transcription and Electroporation of DCs.
In vitro transcription of mRNA from pGEM4Z64A vec-
tors was performed as described previously [9] with Life
Technologies mMESSAGE mMACHINE T7 ULTRA kits
according to the manufacturer’s instructions. DCs were
electroporated with different mRNAs (Table 1) as described
in [10, 22]. As a control, mDCs were electroporated without
mRNA.
2.3. Cell SurfaceMarker Analysis. mDCs were electroporated
as described above, incubated in DC medium at 37∘C in a
humidified incubator, and harvested 24 h after electropora-
tion.The expression of distinct markers was analyzed by flow
cytometry. For the determination of surface marker expres-
sion, the following antibodies and their respective isotype
controls were used: IgG1-PE, anti-CD25-PE, anti-CD40-PE,
anti-CD70-PE, anti-CD80-PE, anti-CD83-PE, anti-CD86-PE
(all from BD), and IgG3-PE (eBioscience). Seventy-five to
one hundred thousand cells were incubated with antibody
for 30 minutes at 4∘C in FACS solution, consisting of PBS
supplemented with 1% FCS (PAA, GE healthcare) and 0.02%
sodium azide (Merck). The cells were then washed once
with FACS solution and immunofluorescence was measured
using a FACScan cytofluorometer equipped with CellQuest
software (BD Biosciences). mDCs were gated on in the
forward and side scatter channels and the mean fluorescence
Journal of Immunology Research 3
intensities (MFIs) were measured. Specific MFI was calcu-
lated by subtraction of the MFI of the isotype control.
2.4. Cytokine Secretion Analysis. mDCs were electroporated
as described above and were incubated in DC medium
at 37∘C in a humidified incubator, and supernatants were
taken 24 h after electroporation. Cytokine concentrations
were analyzed with an Inflammation Cytometric Bead Array
(BD, Heidelberg, Germany) following the manufacturer’s
instructions.
2.5. Statistical Analysis. We performed a 1-way ANOVA with
multiple comparison test (according to Dunnet/Tukey) with
a confidence level of 0.05 using GraphPad Prism V6.02 to
determine statistically significant differences for the surface
staining data (Figure 2) with the unadjusted mean fluores-
cence intensities, the percentage values of positive cells, and
the cytokine concentrations (Figures 3 and 4). For the data
in Figures 2 and 3, the multicomparison was performed
according to Dunnet against the mock condition. For the
data in Figure 4, all conditions were compared to each other
according to Tukey.
2.6. Cryoconservation of Cell Pellets. mDCs were electropo-
rated as described above, were incubated in DC medium
at 37∘C in a humidified incubator, and were harvested 4 h
after electroporation. One to two hundred thousand cells
were centrifuged for 10min at 10.000 rpm at 4∘C and the
supernatant was removed. The cell pellet was frozen and
stored in liquid nitrogen until microarray analysis.
2.7. Microarray Analysis. Cryoconserved electroporated
mDCs were sent to Miltenyi Biotec for microarray analysis.
Cells were lysed, mRNAwas isolated and reverse-transcribed
to cDNA, the cDNA was amplified, and Cy3 was labeled
and then hybridized to Agilent Whole Human Genome
Oligo Microarrays (8 × 60K). Fluorescence signals of
the hybridized Agilent Microarrays were detected using
Agilent’s Microarray Scanner System (Agilent Technologies).
The Agilent Feature Extraction Software (FES) was used
to read out and process the microarray image files. The
resulting text files produced by FES were then processed
for quality control, removing control probes and probes
flagged as unreliable by the scanning software. The raw data
underwent background correction to eliminate background
noise and local fluctuations. To this end, the normal-
exponential convolution method was used (Normexp). Next,
the data were normalized to correct chip-related variations
in the signal intensity (e.g., labeling and hybridization
inefficiencies). To this end, the quantile method with offset =
16 was applied to the data.
Unadjusted 𝑝 values were calculated with Student’s 𝑡-test
and the Benjamini Hochberg method for False Discovery
Rate was used to adjust the 𝑝 value and find differentially
expressed genes. Data processing and analysis were per-
formed in the software R computing environment (version
3.0.2) using the Bioconductor (version 3.1) package “limma”
(linear models for microarray and RNA-seq data) described
in [23].
3. Results
3.1. mRNA Electroporation into Human Cocktail-Matured,
Monocyte-Derived DCs Results in a High Transfection Effi-
ciency. To formally show that mRNA electroporation results
in protein expression in the cocktail-matured, monocyte-
derived DCs, we generated these DCs and electroporated
them either without RNA (mock) or with RNA encoding the
tumor antigen MelanA (Figure 1). These DCs were produced
by a highly standardized and validated process, which is
approved for DC generation for clinical applications [24].
Hence, the product is very well known considering the
phenotype of the DCs.Therefore, we did not include a typical
DC-specific marker in these experiments but rather focused
on maturation and activation markers on these DCs. The
DCs displayed a mature phenotype, which was not altered
by transfection with MelanA-encoding mRNA (Figures 1(a)
and 1(b)). Four and twenty-four hours after electroporation,
the intracellular MelanA expression was determined by flow
cytometry. As shown in Figure 1(c), MelanA expression was
detected at both time-points.The transfection efficiency at 4 h
was >95% (Figure 1(c); left panel). Due to the transiency of
mRNA transfection, the MelanA expression had decreased
at the 24 h time-point (Figure 1(c); right panel). These data
show that the electroporated mRNA enters the cytoplasm of
the vast majority of the mature DCs very efficiently.
3.2. mRNA Electroporation into Human Cocktail-Matured,
Monocyte-Derived DCs Has No Influence on the Phenotype
of These Cells. As it was suggested that introduction of
mRNA could trigger intracellular TLRs or other receptors
[15–21], we examined whether mRNA electroporation has an
influence on the phenotype of cocktail-matured, monocyte-
derived DCs. We electroporated these DCs either without
RNA (Figure 2; mock) or with a panel of 16 different RNAs
encoding tumor antigens, or parts thereof (MelanA, NRAS,
BRAF, GNAQ, GNA11, andWT1), either mutated or not, and
either linked to the lysosomal targeting signal DC-LAMP or
not (Table 1). Twenty-four hours after electroporation, the
surface expression of CD25, CD40, CD86, CD70, and CD83
was determined by flow cytometry. When looking at mean
fluorescence intensities (MFIs), electroporations with the 16
different RNAs encoding different tumor antigens resulted
in differences in cell surface marker expression of less than
1.5-fold compared tomock-electroporatedDCs (Figure 2(a)).
No large differences in expression of these markers were
observed when looking at percent positive cells (Figure 2(b)).
According to a 1-way ANOVAwith multiple comparison test,
no statistically significant differences were present within
the surface staining data (𝑝 > 0.05). We did not measure
expression of MHC-class II, as we had observed before that
there are no big changes on human monocyte-derived DCs,
even after activation of NF-𝜅B (data not shown).
From these data, we can conclude that the introduction
of mRNA into human cocktail-matured, monocyte-derived
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Figure 1: MelanA is expressed in cocktail-matured, monocyte-derived DCs after mRNA electroporation. DCs were either electroporated
without mRNA (mock; gray histogram) or with mRNA encoding the tumor antigen MelanA (MelanA; black histogram). (a) Surface marker
expression of CD25, CD40, CD83, CD86, CD70, and CD80 on mock-electroporated and MelanA-RNA-electroporated DCs 24 h after
electroporation is shown (black lines; respective isotype controls). One representative of ≥4 experiments is shown. (b) Gating of mock-
electroporated (Mock) or MelanA-RNA-electroporated (MelanA) DCs was performed according to forward and side scatter. (c) Four and
twenty-four hours after electroporation, the intracellular MelanA expression was determined by flow cytometry. The percentage of positive
cells is indicated. One representative of >10 experiments is shown.
DCs by electroporation did not result in a relevant change of
the phenotype of these cells.
3.3. mRNA Electroporation into Human Cocktail-Matured,
Monocyte-Derived DCs Has No Influence on the Cytokine
Secretion by These Cells. Next, we investigated whether
mRNA electroporation has an influence on the cytokine
secretion of cocktail-matured, monocyte-derived DCs. We
electroporated DCs either without RNA (Figure 3; Mock)
or with the 16 different RNAs encoding tumor antigens
and harvested the supernatants of the cells 24 h after
electroporation to determine the cytokine secretion in a
cytometric bead array. Within 24 h after electroporation,
the DCs hardly any IL-1𝛽, IL-10, and IL-12p70 (data not
shown) but produced measurable quantities of IL-8, IL-6,
and TNF𝛼 (Figure 3). However, mock-electroporated DCs
also secreted these cytokines, and the electroporations with
the 16 different RNAs, encoding different tumor antigens,
resulted in a difference in cytokine secretion of maximum
1.5-fold compared to mock-electroporated DCs (Figure 3).
According to a 1-way ANOVAwith multiple comparison test,




















































































































































































































































































































































Figure 2: No difference in phenotype between mock- and mRNA-electroporated DCs. DCs were either electroporated without RNA (Mock)
or a panel of 16 RNAs encoding different tumor antigens, either mutated or not and either linked to the lysosomal targeting signal DC-LAMP
or not (see Table 1). Twenty-four hours after electroporation, the surface expression of CD25, CD40, CD86, CD70, and CD83 was determined
by flow cytometry. Surfacemarker expression ofmock-electroporatedDCswas put at 100% andmarker expression after electroporation of the
mRNAs was put in relation to that (a), or percent positive cells are shown (b). Shown are averages of at least 3 independent experiments. Error
bars indicate the standard deviation (SD). According to a 1-way ANOVAwith multiple comparison test, no statistically significant differences
were present within the surface staining data (𝑝 > 0.05).










































































































































Figure 3: No difference in cytokine secretion between mock- and
MelanA-RNA-electroporated DC. DCs were electroporated either
without RNA (Mock) or with a panel of 16 RNAs encoding different
tumor antigens, either mutated or not, and either linked to the
lysosomal targeting signal DC-LAMP or not (see Table 1). Twenty-
four hours after electroporation, supernatants of the cells were
taken and the cytokine secretion by the cells was determined in a
cytometric bead array. Cytokine secretion of mock-electroporated
DCswas defined as 100% and concentrations after electroporation of
themRNAswere put in relation to that. Shown are averages of at least
3 independent experiments. Error bars indicate the standard devia-
tion (SD). According to a 1-way ANOVA with multiple comparison
test, no statistically significant differences were present within the
cytokine secretion data (𝑝 > 0.05).
no statistically significant differences were present within the
cytokine secretion data (𝑝 > 0.05).
These data show that the electroporated mRNAs also
had no relevant influence on cytokine secretion by human
cocktail-matured, monocyte-derived DCs.
Due to the fact that the secretion of IL-8, IL-6, and TNF𝛼
was clear but at low quantities, we wanted to formally prove
that our DCs were able to produce these cytokines at higher
quantities, when properly activated under similar conditions.
Therefore, we electroporated the mature DCs either without
RNA or with RNAs encoding MelanA combined or not
with RNA encoding a constitutively active form of IKK𝛽,
which is, on the protein level, able to activate the NF-𝜅B
pathway in the DCs [10]. Indeed, we saw that transfection
with constitutively active IKK𝛽 resulted in high IL-8, IL-
6, and TNF𝛼 secretion (Figure 4), proving that our DCs
can produce these cytokines at high quantities. In addition,
there was no difference between the cytokine secretion by
mock-transfected and MelanA-transfected DCs (Figure 4),
again showing that mRNA transfection per se did not induce
cytokine production in DCs. The 1-way ANOVA with mul-
tiple comparison test showed that the IKK𝛽-transfected DCs
were highly significantly different from themock andMelanA
conditions but that the mock and MelanA conditions were
not.
3.4. Microarray Analysis Reveals No Differentially Expressed
Genes between Mock- and MelanA-Transfected DCs. Al-
though we found no obvious differences in the expression of
a handful of surface markers and the secretion of half a dozen
of cytokines upon mRNA electroporation, we still could not
exclude that the exogenous mRNA would induce signaling
within the DCs, which, by chance, would regulate other
target genes and modulate the expression of other factors. To
explore in more detail whether mRNA electroporation has
any effect on the transcriptome of the DCs, we performed
GeneChip microarray analyses with matured DCs (mDCs)
of 6 independent donors, which had either been mock-
electroporated or electroporated with MelanA RNA. DCs
were harvested and frozen 4 h after electroporation, and
samples were hybridized to Agilent Whole Human Genome
Oligo Microarrays (8 × 60K). Fluorescence signals of the
hybridized Agilent Microarrays were determined, prepro-
cessed, and normalized. Afterwards, differentially expressed
genes were calculated and significance was examined by
Student’s 𝑡-test and subsequent adjustment using the Ben-
jamini Hochberg method for False Discovery Rate. These
calculations were performed using the limma (linear models
for microarray and RNA-seq data) software package for the
Bioconductor R computing environment [23] (see Section 2).
The expression levels of all the microarray probes are com-
pared directly in Figure 5 to depict the degree of difference
between the two sample groups. The scatter plot shows
that the individual values are close to the identity function
(Figure 5), except for a small number of outliers, of which
none was significant (Figure 5). Indeed, none of the probes
showed a significant difference betweenmock-electroporated
DCs and MelanA-electroporated DCs, and the adjusted 𝑝
values were all above 0.99995, indicating that no differentially
expressed genes (DEGs) were present. This suggests that
the difference at the transcriptional level between mock-
electroporated DCs and MelanA-electroporated DCs is neg-
ligible.
4. Discussion
In this study, we have shown that electroporation of antigen-
encoding RNA into matured monocyte-derived dendritic
cells (moDCs) had no influence on the phenotype of these































































Figure 4: Massive cytokine secretion after electroporation with mRNA encoding a DC-activating protein. DCs were electroporated either
without RNA (Mock) or with RNA encoding the tumor antigen MelanA (MelanA) or MelanA and constitutively active stabilized mutated
IKK𝛽. Twenty-four hours after electroporation, supernatants of the cells were taken and the cytokine secretion by the cells was determined
in a cytometric bead array. The cytokine concentrations in the supernatants are depicted. Each symbol represents an individual donor, tested
in an independent experiment (𝑛 = 8). The horizontal bars show the average values. 𝑝 values were calculated by the 1-way ANOVA with
multiple comparison test (according to Tukey) with a confidence level of 0.05; ns: 𝑝 > 0.05, ∗∗∗𝑝 ≤ 0.001, and ∗∗∗∗𝑝 ≤ 0.0001.
DCs and on the cytokine secretion by these DCs and even
that there was no influence of the RNA on the transcriptome
of the DCs. This is pivotal information for the use of
mRNA-electroporated moDCs in a clinical setting, since
it is necessary to generate vaccines of consistent quality
by a stable production process, no matter what antigen-
encoding RNA is used for electroporation, and it shows that
our matured moDCs are of a robust phenotype. Since we
[9] and others [8, 11, 25] observed that DCs, which were
antigen-electroporated after cytokine-maturation, seemed to
perform better, we limited our analysis to DCs matured and
electroporated in that order. Hence, we cannot say anything
about the influence of mRNA electroporation into DCs
prior to maturation and can only speculate that immature
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Figure 5: No difference in microarray analysis between mock-
and MelanA-RNA-electroporated DCs. Scatter plot of the probe
set expression levels for MelanA-RNA-electroporated DCs versus
Mock-electroporated DCs samples. Data from 6 samples per exper-
imental condition were processed for background correction and
normalization. In the figure, the average probe intensity for each
experimental condition is visualized.
DCs might be more susceptible for mRNA-mediated signals.
However, this should be investigated in separate studies and
is beyond the scope of this paper.
Other researchers have indeed observed mRNA-induced
maturation of DCs, however under different experimental
conditions [19, 26]. Ceppi and coworkers, who worked with
porcinemonocyte-derived DCs, observed that DC activation
can occur after exogenous delivery of mRNA. Lipofection of
mRNA inducedmaturation of immature porcineDCs, that is,
MHC class II and CD80/CD86 upregulation [19]. An impor-
tant element therein is the lipofection-induced production
of type I IFN by the DCs, which also showed evidence of
maturation. The DC activation was caused by the double-
stranded secondary structures formed by the transfected
mRNA, and the effect depended on the quantity of lipofected
mRNA [19]. It is well established that viral or synthetic
double-stranded RNA (dsRNA) acts as a danger signal to
DCs, inducing them to produce IFN𝛼/𝛽 and to mature [27].
Furthermore, it was reported that mRNA lipofection has the
capacity to activate DCs (humanmoDCs) [26].These authors
noted the upregulation of activation markers, like CD25,
CD80, CD83, CD86, MHC class I, and MHC class II, and
cytokine production, like IL-12, IFN𝛼, and TNF𝛼 [26].
Although our different antigen-encoding mRNAs can
fold and form dsRNA stretches according to the Mfold Web
Server (http://unafold.rna.albany.edu/?q=mfold/RNA-Fold-
ing-Form) [28] and thus in theory can also stimulate dsRNA-
sensing receptors, we did not observe any DC activation.This
can be explained by two main differences of our experiments
compared to the experimental setup used by Ceppi et al. and
Ni et al.
We usedmoDCs, which had beenmaturedwith a cocktail
containing IL-1𝛽, TNF𝛼, IL-6, and PGE
2
before the mRNA
was introduced, while in the other publications the mRNA
was introduced into immature DCs. It might be that the weak
stimulus of the introduced mRNA is just not able to change
the robust mature phenotype of the cytokine-matured DCs.
However, sensing of RNA by receptors should still induce a
difference in the transcriptome.
Therefore, it is more plausible that our antigen-encoding
RNAs are simply not sensed by the corresponding receptors,
because they do not reach the compartments containing
these receptors. Indeed it was shown that the RNA must
reach the active TLRs in the endolysosomal compartment
to be recognized by TLR7, TLR8, and TLR9 and that self-
nucleic acids do not enter the TLR-sensing compartment
under normal physiological conditions (reviewed in [13]).
Only after entering the endolysosomal compartment, the
TLRs are activated upon cleavage by resident pH-dependent
proteases. This mechanism prevents that self-nucleic acids at
different locations in the cell are recognized by the TLRs.
Once activated, the TLRs themselves cannot distinguish
between foreign and self-nucleic acids; however, the latter
do not encounter the active receptors [29]. Normal “naked”
mRNA is rapidly degraded by endolysosomal RNas before
the receptor is activated. However, if the RNA is protected by
lipids, which is the case with lipofection in the publications
of Ceppi et al. and Ni et al., or stabilized by protamine [30],
or protected by virus particles (reviewed in [13]), it is stable
enough to enter the endolysosomal compartment where it is
recognized by the activated TLRs resulting in an activation of
the DCs.
5. Conclusion
Taken together, our data show that electroporation of mature
monocyte-derivedDCswith antigen-encodingRNAdoes not
deliver a danger signal to the DCs and does not result in
a change of the DCs. This is important knowledge for the
scientific community using these DCs in vaccination trials,
where a stable and robust cell type is needed.
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